Compare · RZLT vs XOMA
RZLT vs XOMA
Side-by-side comparison of Rezolute Inc. (RZLT) and XOMA Royalty Corporation (XOMA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RZLT and XOMA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- XOMA is the larger of the two at $503.8M, about 1.1x RZLT ($443.9M).
- Over the past year, RZLT is down 14.5% and XOMA is up 55.1% - XOMA leads by 69.6 points.
- XOMA has been more active in the news (13 items in the past 4 weeks vs 3 for RZLT).
- RZLT has more recent analyst coverage (15 ratings vs 7 for XOMA).
- Company
- Rezolute Inc.
- XOMA Royalty Corporation
- Price
- $4.60+5.50%
- $40.32-8.74%
- Market cap
- $443.9M
- $503.8M
- 1M return
- +0.77%
- -3.49%
- 1Y return
- -14.50%
- +55.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1986
- News (4w)
- 3
- 13
- Recent ratings
- 15
- 7
Rezolute Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
XOMA Royalty Corporation
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; Takeda Pharmaceutical Company Limited; and Cadila Healthcare Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Latest RZLT
- Chief Medical Officer Roberts Brian Kenneth covered exercise/tax liability with 3,062 shares, decreasing direct ownership by 1% to 293,851 units (SEC Form 4) (withholding tax)
- CEO Elam Nevan C covered exercise/tax liability with 8,004 shares, decreasing direct ownership by 1% to 605,497 units (SEC Form 4) to satisfy tax liability
- CFO Evans Daron covered exercise/tax liability with 3,062 shares, decreasing direct ownership by 0.74% to 411,400 units (SEC Form 4) (for withholding tax)
- Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
- Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
- Rezolute upgraded by Citizens with a new price target
- Rezolute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
- SEC Form SCHEDULE 13G filed by Rezolute Inc.
- SEC Form 10-Q filed by Rezolute Inc.
Latest XOMA
- SEC Form 4 filed by Large owner Bvf Partners L P/Il
- Chief Legal Officer Montano Maricel Perea disposed of 42,371 shares, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Director Limber Joseph M disposed of 9,532 shares, returned 10,000 units of 8.625% Series A Cumulative Perpetual Preferred Stock to the company and returned 20,000 units of Depositary Shares - 8.375% Series B Cumulative Stock to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Chief Investment Officer Sitko Bradley disposed of 86,702 shares, returned 395 units of 8.625% Series A Cumulative Perpetual Preferred Stock to the company and returned 9,045 units of Depositary Shares - 8.375% Series B Cumulative Stock to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Chief Executive Officer Hughes Owen disposed of 192,016 shares and returned 102,000 units of Depositary Shares - 8.375% Series B Cumulative Stock to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Director Kosacz Barbara disposed of 6,269 shares, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Director Wyszomierski Jack L disposed of 21,828 shares, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Director Perry Matthew D disposed of 24,138 shares, closing all direct ownership in the company (SEC Form 4) (withholding obligation)
- Director Hernday Natasha disposed of 9,304 shares and returned 4,000 units of 8.625% Series A Cumulative Perpetual Preferred Stock to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Financial Officer Trigilio Jeffrey disposed of 103,906 shares, closing all direct ownership in the company (SEC Form 4) (withholding obligation)